Key result
Complete antithrombin replacement was required to achieve an activated coagulation time near 480 s for safe cardiopulmonary bypass in a patient with severe infective endocarditis.
Case Report (n=1)
Severe systemic inflammation in infective endocarditis may necessitate extraordinary exogenous antithrombin administration to achieve adequate anticoagulation for cardiopulmonary bypass.
Answers are grounded in this paper and cite their sources.
Potential antithrombin resistance in endocarditis may necessitate individualized dosing; leaves open need for prospective studies.
: We present a case of a 26-year-old patient with severe infective endocarditis complicated with cerebral septic emboli that required essentially complete replacement of his circulating antithrombin activity to achieve an activated coagulation time near 480 s. The need for this degree of antithrombin administration may have been secondary to ongoing systemic inflammation and consequent thrombin generation despite blood culture results demonstrating no bacteremia. In sum, ongoing loss of endogenous antithrombin activity secondary to inflammation and the need for more than 80% normal activity to conduct safe cardiopulmonary bypass may require extraordinary administration of exogenous antithrombin in similar settings.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2017) conducted a case report in severe infective mitral valve endocarditis (n=1). Complete antithrombin replacement was evaluated on activated coagulation time near 480 s. Complete antithrombin replacement was required to achieve an activated coagulation time near 480 s for safe cardiopulmonary bypass in a patient with severe infective endocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: